Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
GenScript
Ranibizumab Monoclonal Antibody (6C3)
Promotions
View available promotion(s)
Promo Code: RPUZZ25 Stock up on essentials to piece your discovery together Until June 27, save up to $650 and get an exclusive lab-themed hidden-object puzzle. Learn more
Application
FIGURE: 1 / 3
Ranibizumab Antibody (A02035-40) in ELISA
Standard curve of Ranibizumab Sandwich ELISA. The Ranibizumab Sandwich ELISA assay is developed by using Anti-Ranibizumab Antibody (6C3), mAb, Mouse (GenScript, A02035-40) and Anti-Ranibizumab Antibody (10D12), mAb, Mouse (GenScript, A02036-40) as the capture and detection antibodies, respectively. In this ELISA assay, Anti-Ranibizumab Antibody (10D12), mAb, Mouse (GenScript, A02036-40) was labeled with Biotin. GenScript can provide customized conjugation services for this product per the customer's request. The Sensitivity of detecting Ra... View More
Product Details
A02035-40
Product Specifications
Species Reactivity
Human
Host/Isotype
Mouse
/ IgG1, lambda
Class
Monoclonal
Type
Antibody
Clone
6C3
Immunogen
Ranibizumab
Conjugate
Unconjugated
Form
Lyophilized
Purification
Protein A
Storage buffer
PBS, pH 7.4
Contains
0.02% sodium azide
Storage conditions
-20°C or -80°C if preferred
Shipping conditions
Ambient (domestic); Wet ice (international)
Product Specific Information
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity.Anti-Ranibizumab Antibody (6C3), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Ranibizumab.
Target Information
Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support